SCHEMBL25399754

SCHEMBL25399754

Cc1[nH]c2ccc(F)cc2c1CC(C)N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.55
HTR2C P28335 2/20 0.55
KDM4E B2RXH2 4/20 0.43
KIF11 P52732 1/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
HTR6 P50406 3/20 0.42
HTR1D P28221 2/20 0.42
HTR7 P34969 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTR3A P46098 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 2/20 0.42
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30501959 1.00 HTR2A (0.55) HTR2AHTR2CKDM4EKIF11KEAP1
SCHEMBL23259264 0.88 KIF11 (0.45) HTR2AHTR2CKDM4EKIF11KEAP1
SCHEMBL19192790 0.79 SMN1; SMN2 (0.53) HTR2AHTR2CKDM4EKIF11KEAP1
SCHEMBL14021954 0.79 KDM4E (0.48) KDM4EKIF11KEAP1NFE2L2HTR6
SCHEMBL8244089 0.78 HTR6 (0.68) HTR2AKDM4EKIF11KEAP1NFE2L2
SCHEMBL23259133 0.78 KIF11 (0.47) HTR2AHTR2CKDM4EKIF11KEAP1
SCHEMBL15281761 0.78 MAPT (0.57) HTR2AHTR2CKDM4EHTR6HTR1D
SCHEMBL15281774 0.78 MAPT (0.57) HTR2AHTR2CKDM4EHTR6HTR1D
Hydrochloric Acid SCHEMBL21546038 0.77 HTR6 (0.66) HTR2AKDM4EKIF11KEAP1NFE2L2
SCHEMBL15150611 0.75 HTR6 (0.46) HTR2AHTR2CKDM4EKIF11KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257347-A1 ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-08-17 US disclosed
US-20230257347-A1 ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-08-17 US disclosed
US-20230257347-A1 ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257347-A1 ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT HTR6, TPH2, TPH1 HTR2A 13/4885HTR2C 23/4885KDM4E 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.